Targanta Therapeutics Corp. - Current report filing (8-K)
August 07 2008 - 8:31AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): August 7, 2008
Targanta Therapeutics Corporation
(Exact Name of Registrant as Specified in
Its Charter)
|
|
|
Delaware
|
(State or Other Jurisdiction
of Incorporation)
|
|
|
1-33730
|
|
20-3971077
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
222 Third Street, Suite 2300
Cambridge, MA
|
|
02142-1122
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
(617) 577-9020
(Registrants Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, If Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
INFORMATION TO BE INCLUDED IN THE REPORT
Item 2.02.
|
Results of Operations and Financial Condition.
|
On
August 7, 2008, Targanta Therapeutics Corporation (the
Company
) issued a press release announcing its financial results for the three months and six months ended June 30, 2008. The full text of the press release is
attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Form 8-K (including Exhibit 99.1) shall not be deemed
filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
Exchange Act
) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in
any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
|
|
|
99.1
|
|
Press Release of the Company, dated August 7, 2008.
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
TARGANTA THERAPEUTICS CORPORATION
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Daniel S. Char
|
Date: August 7, 2008
|
|
|
|
Daniel S. Char
|
|
|
|
|
|
|
Vice President, General Counsel and Secretary
|
3
EXHIBIT INDEX
|
|
|
Exhibit No.
|
|
Description of Exhibit
|
99.1
|
|
Press Release of the Company, dated August 7, 2008.
|
4
Targanta Therapeutics Corp (MM) (NASDAQ:TARG)
Historical Stock Chart
From Sep 2024 to Oct 2024
Targanta Therapeutics Corp (MM) (NASDAQ:TARG)
Historical Stock Chart
From Oct 2023 to Oct 2024